Abstract

Of the 5.4 million people in the United States who have had a stroke, half may have related motor and cognitive disabilities. Nearly one-quarter of stroke survivors need physical assistance in everyday life, and cognitive symptoms may have an equal or greater impact on function compared with physical limitations [1-3]. These numbers are frightening when we realize that health outcome studies in stroke may underrepresent the magnitude of the problem. Persons with disabilities who enter supervised or chronic-care settings may not be included in databases or research studies, and stroke survivors with cognitive disabilities may also fail to participate in research because of behavioral abnormalities, such as abnormal arousal and motivation, communication disorders, or the inability to coordinate activities and comply with study protocols. Although meticulous poststroke medical care is reducing stroke-related mortality in the United States, the number of survivors living with stroke-related disabilities may significantly increase as a result [4]. Thus, rehabilitation scientists are challenged to develop better and more effective treatments for cognitive and motor dysfunction so that people may return to satisfying life activities. Neuroscience researchers routinely suggest that investigation of the mechanisms of stroke-related cognitive and motor deficits will inspire new treatments. However, basic research in poststroke deficits may only describe the correlates of disability rather than the degree of disability and may include subjects with subtle signs who would not ordinarily meet the clinical criteria for treatment. Thus, we as clinicians may have difficulty generalizing and applying the results of basic science experiments to the treatment of patient groups in a valid fashion. Most clinical researchers are aware of this limitation and regard mechanistic studies as a first step toward the development of treatment-valid research. How to move from basic discovery toward large-scale, systematic clinical studies is not always as clear to the rehabilitation community [5]. That within-subject, exploratory, and experimental designs advance research questions and bridge the gap to randomized group studies may not be acknowledged. Scientists may criticize early phase clinical trial studies because they do not use randomized controls or meta-analysis, which are characteristic of phase III studies. However, the methodology of phase III research is neither appropriate nor desirable when a research question is innovative, being refined, and being explored for its feasibility and optimal setting. An unfortunate truth is that even after quality randomized clinical trials of a treatment are available and the benefits indicated, problems occur when practitioners apply them to the treatment of individual patients. As practitioners apply a developed treatment, they may discover that the results do not generalize or do not apply to certain patients. Systematic investigation of these particular patients will give rise to data-refining clinically valid practice [6-7]. Such patients may belong to groups who were excluded or underrepresented in the formal trial but are frequently encountered in the aged population, such as patients with multiple chronic medical problems. Other understudied groups include women; members of ethnic, racial, and cultural minorities; rural dwellers; and the poor. Averaged results from patients with diverse presentations of a clinical disorder in a large-scale clinical trial also may not represent the treatment-response spectrum. Patients with some theoretically defined subtypes of a clinical disorder may benefit, while others may experience adverse effects. Unless appropriate secondary analyses are performed, this disparity in response may go undetected and the trial reported as lacking any treatment benefit [8-9]. Such reexamination of gold standard results is desirable and, indeed, inevitable, as paradigm shifts in the field of cognitive rehabilitation help us redefine the brain-behavior mechanisms of the disorders that we treat. …

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.